Cardiology

Your daily dose of clinical news you may have missed.

The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.

Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.

Sales of e-cigarettes in the US jumped by 46% from 2020-2022; rapid market shifts beg coordinated restrictions to protect public health, says the CDC.

Your daily dose of clinical news you may have missed.

Retatrutide, survodutide, orforglipron. The 3 new GLP-1 agonist-based AOMs showed weight loss of up to 20% and are well worth watching.

Your daily dose of clinical news you may have missed.

ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

Your daily dose of clinical news you may have missed.

Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.

Your daily dose of clinical news you may have missed.

Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.

Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.

ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.

Your daily dose of clinical news you may have missed.

Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.

ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Oral estrogen hormone therapy was more likely to result in incident hypertension than transdermal or vaginal formulations in this large prospective population-based study.

Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.

Increased levels of lipoprotein(a) significantly and independently predicted recurrent CHD events in adults aged 60 years and older, report study authors.

FDA fast tracks triple-threat antithrombotic, dangers of faux semaglutide online, a guide to neurologic sequelae of COVID-19, plus 2 more reviews of note.

Proposed indications for the investigational factor XIa inhibitor are: stroke prevention after acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.